High-precision stereotactic irradiation for focal drug-resistant epilepsy versus standard treatment: a randomized waitlist-controlled trial (the PRECISION trial)

Author:

Zegers C. M. L.ORCID,Swinnen A.,Roumen C.,Hoffmann A. L.,Troost E. G. C.,van Asch C. J. J.,Brandts L.,Compter I.,Dieleman E. M. T.,Dijkstra J. B.,Granzier M.,Hendriks M.,Hofman P.,Houben R. M. A.,Ramaekers B.,Ronner H. E.,Rouhl R. P. W.,van der Salm S.,Santegoeds R. G. C.,Verhoeff J. J.,Wagner G. L.,Zwemmer J.,Schijns OEMG,Colon A. J.,Eekers D. B. P.

Abstract

Abstract Introduction The standard treatment for patients with focal drug-resistant epilepsy (DRE) who are not eligible for open brain surgery is the continuation of anti-seizure medication (ASM) and neuromodulation. This treatment does not cure epilepsy but only decreases severity. The PRECISION trial offers a non-invasive, possibly curative intervention for these patients, which consist of a single stereotactic radiotherapy (SRT) treatment. Previous studies have shown promising results of SRT in this patient population. Nevertheless, this intervention is not yet available and reimbursed in the Netherlands. We hypothesize that: SRT is a superior treatment option compared to palliative standard of care, for patients with focal DRE, not eligible for open surgery, resulting in a higher reduction of seizure frequency (with 50% of the patients reaching a 75% seizure frequency reduction at 2 years follow-up). Methods In this waitlist-controlled phase 3 clinical trial, participants are randomly assigned in a 1:1 ratio to either receive SRT as the intervention, while the standard treatments consist of ASM continuation and neuromodulation. After 2-year follow-up, patients randomized for the standard treatment (waitlist-control group) are offered SRT. Patients aged ≥ 18 years with focal DRE and a pretreatment defined epileptogenic zone (EZ) not eligible for open surgery will be included. The intervention is a LINAC-based single fraction (24 Gy) SRT treatment. The target volume is defined as the epileptogenic zone (EZ) on all (non) invasive examinations. The seizure frequency will be monitored on a daily basis using an electronic diary and an automatic seizure detection system during the night. Potential side effects are evaluated using advanced MRI, cognitive evaluation, Common Toxicity Criteria, and patient-reported outcome questionnaires. In addition, the cost-effectiveness of the SRT treatment will be evaluated. Discussion This is the first randomized trial comparing SRT with standard of care in patients with DRE, non-eligible for open surgery. The primary objective is to determine whether SRT significantly reduces the seizure frequency 2 years after treatment. The results of this trial can influence the current clinical practice and medical cost reimbursement in the Netherlands for patients with focal DRE who are not eligible for open surgery, providing a non-invasive curative treatment option. Trial registration Clinicaltrials.gov Identifier: NCT05182437. Registered on September 27, 2021.

Funder

Zorginstituut Nederland

Publisher

Springer Science and Business Media LLC

Reference54 articles.

1. “Nivel Zorgregistraties eerste lijn.”. Available: https://www.volksgezondheidenzorg.info/onderwerp/epilepsie/cijfers-context/huidige-situatie#node-prevalentie-epilepsie-huisartsenpraktijk

2. Thijs RD, Surges R, O’Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393(10172):689–701. https://doi.org/10.1016/S0140-6736(18)32596-0.

3. Nevalainen OPO, Ansakorpi H, Auvinen A. Epilepsy-related clinical characteristics and mortality: a systematic review and meta-analysis. Neurology. 2015;84(17):1823–4.

4. Forsgren L, Hauser WA, Olafsson E, Sander JW, Sillanpää M, Tomson T. Mortality of epilepsy in developed countries: a review. Epilepsia. 2005;46 Suppl 11:18–27. https://doi.org/10.1111/j.1528-1167.2005.00403.x.

5. Pixsil, “Epilepsiechirurgie,” Epilepsiefonds. Available: https://www.epilepsie.nl/over-epilepsie/pagina/101-2/epilepsiechirurgie. Accessed: 17 Mar 2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3